Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab + regorafenib in previously treated MSS advanced colorectal cancer
ChiCTR2100052072Phase 2Not yet recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and regorafenib in colorectal cancer (CRC) and colorectal adenocarcinoma, sponsored by Shanxi Cancer Hospital. Primary endpoint: Objective response rate. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
sintilimabregorafenib
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100052072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052072.